Last reviewed · How we verify
CD19CART
At a glance
| Generic name | CD19CART |
|---|---|
| Also known as | CD19-directed chimeric antigen receptor modified T cells |
| Sponsor | Innovative Cellular Therapeutics Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma (PHASE1)
- Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia (PHASE1)
- Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD19CART CI brief — competitive landscape report
- CD19CART updates RSS · CI watch RSS
- Innovative Cellular Therapeutics Co., Ltd. portfolio CI